In a clinical setting, a toddler born deaf sits in silence as a tone plays. There is no reaction; his expression remains unchanged. Six weeks later, following a single injection of an experimental gene therapy, the child returns to the same room. When the tone plays again, the toddler turns his head toward the sound. When his grandfather speaks his name from off-screen, the boy looks. He can hear.
This transformation is the result of a breakthrough in genetic medicine that has moved from experimental trials to regulatory approval. On April 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Otarmeni
, a gene therapy developed by the pharmaceutical company Regeneron. The treatment targets severe-to-profound hearing loss caused by mutations in the OTOF gene, providing a working copy of the gene directly to the patient’s cells via a National Priority Voucher.
The clinical success of the therapy is reflected in the data from pivotal trials. According to Regeneron, 80 percent of treated patients gained measurable hearing, and 42 percent reached a level of hearing sufficient to perceive whispers in official company filings. Long-term data from the underlying multi-center trial indicates that 90 percent of patients were still experiencing hearing benefits two and a half years after the initial treatment according to reports from Mass General Brigham.
For the families involved, the results have been profoundly emotional. Dr. Yilai Shu of the Eye & ENT Hospital of Fudan University, who co-led the trial, described the moment of realization for the parents.
When the parents realized their child had a response to sound they cried. The whole family cried.Dr. Yilai Shu, Eye & ENT Hospital of Fudan University
The Evolution of Gene Therapy: From Crisis to Clinical Success
The current success of therapies like Otarmeni follows a volatile history for the field of genetic medicine. In 1999, the industry nearly collapsed following the death of Jesse Gelsinger, a teenager who died four days after receiving an experimental injection at the University of Pennsylvania. Gelsinger’s death was the first publicly identified fatality in a gene therapy clinical trial, leading to a sharp decline in funding and a period of intense regulatory scrutiny as documented by the Science History Institute.
The tragedy was rooted in the delivery mechanism. The therapy used on Gelsinger utilized an adenovirus, which is highly immunogenic. This means the human immune system often recognizes the virus and reacts violently, which in Gelsinger’s case proved fatal according to biomedical research. In the wake of this event, the FDA halted several trials and the National Institutes of Health (NIH) tightened oversight. James Wilson, the principal investigator of the Penn study, was stripped of administrative titles and barred from conducting clinical trials for five years.
The field’s recovery was driven by two primary technological shifts. First, researchers transitioned to adeno-associated viruses (AAV). AAV vectors are smaller and more tolerable than adenoviruses, allowing them to deliver genetic payloads into cells without triggering a massive immune response. AAV vectors serve as the foundation for many modern in vivo therapies, including Otarmeni.
The second shift arrived in 2012 with the adaptation of CRISPR by Jennifer Doudna and Emmanuelle Charpentier. Unlike AAV, which delivers a new copy of a gene, CRISPR allows scientists to find a specific location in a patient’s DNA and rewrite the genetic code to correct a mutation in place according to the Nobel Prize in Chemistry 2020 announcement. This precision sparked a renewed influx of capital and talent into regenerative medicine.
A Growing Portfolio of FDA-Approved Therapies
The shift from “cautionary tale” to “ordinary medicine” is evident in the increasing number of FDA approvals for inherited diseases. The trajectory began in December 2017 with the approval of Luxturna, the first U.S. Gene therapy for an inherited disease, targeting hereditary blindness caused by RPE65 mutations as reported by NPR. This was followed in 2019 by Zolgensma, designed to treat spinal muscular atrophy, a wasting disease that can be fatal to children under the age of two.
More recent approvals have expanded the scope of these treatments. In 2022, Hemgenix provided a one-shot fix for hemophilia B according to BioPharma Dive. In 2023, the FDA approved Casgevy and Lyfgenia for the treatment of sickle cell disease, with Casgevy marking the first approved CRISPR-based therapy via official FDA announcements.
The sickle cell approvals are particularly significant because they address a larger patient population—approximately 100,000 Americans—many of whom are from historically underserved Black communities according to CDC data. This proves that gene therapy can be scaled beyond ultra-rare “orphan” diseases.
Beyond hearing and blood disorders, other applications are in development. Verve Therapeutics is utilizing base editing to target the PCSK9 gene to lower LDL cholesterol, potentially replacing daily statins for high-risk cardiovascular patients. Early trial data indicated an average drop in LDL cholesterol of 53 percent according to company data. Other trials are currently exploring treatments for Pompe disease and various forms of hereditary blindness.
The Economic and Cultural Challenges of “Miracle” Cures
Despite the clinical triumphs, the business of gene therapy faces a daunting pricing crisis. Because these treatments are often one-time cures rather than lifelong prescriptions, their list prices are among the highest in medical history.
The financial barrier is acute for diseases with larger populations. For example, two-thirds of U.S. Sickle cell patients rely on Medicaid, and only 16,000 are currently eligible for Casgevy under its existing label according to CNBC reporting. Regeneron has pledged to provide Otarmeni for free in the U.S., but this is feasible only because the patient pool is extremely small—estimated at just 50 babies per year according to BioPharma Dive.
Beyond economics, the ability to “cure” deafness raises complex cultural questions. Since the 1980s, cochlear implants have been a point of contention within Deaf culture, with many advocates arguing that deafness is a distinct identity and a cultural community rather than a deficit to be erased according to research published by ASHA. Gene therapy applied to infants is particularly fraught because the children cannot consent to the permanent alteration of their identity.
The Limits of Current Genetic Medicine
While the restoration of hearing is a landmark achievement, it is important to distinguish between single-gene disorders and polygenic conditions. The inner ear is an ideal target for gene therapy because it is physically accessible and OTOF is a single-gene mutation. In contrast, conditions like Alzheimer’s disease or schizophrenia are polygenic, meaning they are caused by the interaction of multiple genes and environmental factors.
The brain’s complexity and the nature of these diseases mean that the platform working in a child’s ear in 2026 is not a blueprint for universal cures of neurodegenerative diseases in the immediate future. The next decade of research will focus on whether these results can be replicated for more common disorders and whether the pricing models can be restructured to build these treatments accessible to the general public.
For parents facing a rare-disease diagnosis, the paradigm has shifted. The primary question is no longer whether a gene therapy is possible, but how quickly it can move through the clinical trial pipeline to reach the bedside.
As the medical community monitors the rollout of Otarmeni, the next critical checkpoint will be the long-term follow-up data on the first cohort of FDA-approved patients to determine the permanence of the hearing restoration.
We invite our readers to share their perspectives on the ethical and economic implications of gene therapy in the comments below.